Novel Anti-Platelets in Stable Coronary Artery Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|29|4537-4567

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.29, 2016-09, pp. : 4537-4567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Roxifiban promising in stable coronary artery disease

By  

Inpharma, Vol. 1, Iss. 1386, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Revascularization treatment of stable coronary artery disease

By Magro Michael   Garg Scot   Serruys Patrick W  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 195-212

Informa Healthcare

Access to resources Recommend Favorite

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

By Murphy J.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 2, 2003-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

By Malinin A.I.   Atar D.   Callahan K.P.   McKenzie M.E.   Serebruany V.L.  

European Journal of Pharmacology, Vol. 462, Iss. 1, 2003-02 ,pp. : 139-143

Elsevier

Access to resources Recommend Favorite

Effects of the Coronary Collateral Circulation on the Tp-e Interval and Tp-e/QT Ratio in Patients with Stable Coronary Artery Disease

By  

Annals of Noninvasive Electrocardiology, Vol. 20, Iss. 1, 2015-01 ,pp. : 53-61

Blackwell Publishing

Access to resources Recommend Favorite